Form 4: Clene Inc. CFO Acquires 10,000 Stock Options

Clene Inc.'s Chief Financial Officer, Morgan R Brown, was granted options to purchase 10,000 shares of common stock at an exercise price of $5.15 on August 16, 2024.

Summary

• On August 16, 2024, Morgan R Brown, the Chief Financial Officer of Clene Inc., was granted stock options.
• The options allow Brown to purchase 10,000 shares of Clene Inc. common stock.
• The exercise price for these options is $5.15 per share.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan.
• The options vest in 1/12th increments monthly, starting September 16, 2024, until fully vested.
• The options expire on August 15, 2034.

Sentiment

Score: 6

Explanation: The document is neutral, simply reporting a standard executive compensation practice. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the CFO to drive company performance.
• Employees may see this as a standard practice for executive compensation.

Key Dates